The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma

Clinical Cancer Research

Volumn 5, Issue 8, 1999, Pages 2205-2212

  Miknyoczki, Sheila J ^a   Chang, Hong ^a   Klein Szanto, Andres ^b   Dionne, Craig A ^a   Ruggeri, Bruce A ^a  

^a CEPHALON INC   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEP 701; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER INVASION; CANCER REGRESSION; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS DUCT; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CARBAZOLES; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLES; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; RATS; RECEPTOR, TRKA; TIME FACTORS; TRACHEA; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 0032771840     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Noble, S., and Goa, K. L. Gemcitabine. Drugs, 54, 447-472, 1997.
2. Link, K. H., Gansauge, F., Gorich, J., Leder, G. H., Rilinger, N., and Beger, H. G. Palliative and adjuvant regional chemotherapy in pancreatic cancer. Eur. J. Surg. Oncol., 23: 409-414, 1997.
3. Farrell, T. J., Barbot, D. J., and Rosato, F. E. Pancreatic resection combined with intraoperative radiation therapy for pancreatic cancer. Ann. Surg., 226: 66-69, 1997.
4. Regine, W. F., John, W. J., and Mohiuddin, M. Current and emerging treatments for pancreatic cancer. Drugs Aging, 11: 285-295, 1997.
5. Chen, L. M., Haraf, D., Brachman, D. G., Vokes, E. E., and Schilsky, R. L. Concomitant 5-FU, hydroxurea and cisplatin with external beam radiation therapy for locally advanced pancreatic cancer: a Phase II study. Oncol. Rep., 4: 877-881, 1997.
6. Hahn, S. A., and Kern, S. E. Molecular genetics of exocrine pancreatic neoplasms. Surg. Clin. N. Am., 75: 857-869, 1995.
7. Ruggeri, B. A., Huang, L., Berger, D., Chang, H., Klein-Szanto, A. J. P., Goodrow, T., Wood, M., Obara, T., Heath, C. W., and Lynch, H. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions. Cancer (Phila.), 79: 700-716, 1997.
8. Murr, M. M., Sarr, M. G., Oishi, A. J., and van Heerden, J. A. Pancreatic cancer (Review). CA Cancer J. Clin., 44: 304-318, 1994.
9. Hruban, R. H., van Mansfeld, A. D. M., Offerhaus, G. J. A., van Weering, D. H. J., Allison, D. C., Goodman, S. N., Kensler, T. W., Bose K. K., Cameron, J. L., and Bos, J. L. K-ras activation in adenocarcinoma of the human pancreas. Am. J. Pathol., 143: 545-554, 1993.
10. DiRenzo, M. F., Poulsom, R., Olivero, M., Comoglio, P. M., and Lemoine, N. R. Expression of the met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res., 55: 1129-1138, 1995.
11. Ebert, M., Yokoyama, M., Kobrin, M. S., Friess, H., Lopez, M. E., Buchler, M. W., Johnson, G. R., and Korc, M. Induction and expression of amphiregulin in human pancreatic cancer. Cancer Res., 54: 3959-3962, 1994.
12. Ebert, M., Yokoyama, M., Friess, H., Kobrin, M. S., Buchler M. W., and Korc, M. Induction of platelet-derived growth factor A and B chains and over-expression of their receptors in human pancreatic cancer. Int. J. Cancer, 62: 529-535, 1995.
13. Friess, H., Yamanaka, Y., Buchler, M., Beger, H. G., Kobrin, M. S., Baldwin, R. L., and Korc, M. Enhanced expression of the type II transforming growth factor beta receptor in human pancreatic cancer cells without alternation of type III receptor expression. Cancer Res., 53: 2704-2707, 1993.
14. Friess, H., Berberat, P., Schilling, M., Kunz, J., Korc., M., and Buchler, M. W. Pancreatic cancer: the potential clinical relevance of alternations in growth factors and their receptors. J. Mol. Med., 74: 35-42, 1996.
15. Miknyoczki, S. J., Lang, D., Huang, L., Klein-Szanto, A. J. P., Dionne, C. A., and Ruggeri, B. A. Neurotrophins and Trk receptors in human pancreatic ductal adenocarcinoma: expression patterns and effects on in vitro invasive behavior. Int. J. Cancer, 81: 417-427, 1999.
16. Camoratto, A. M., Jani, J. P., Angeles, T. S., Maroney, A. C., Sanders, C. Y., Murakata, C., Neff, N. C., Vaught, J. L., Issacs, J. T., and Dionne, C. A. CEP-751 inhibits Trk receptor tyrosine kinase activity in vitro and exhibits anti-tumor activity. Int. J. Cancer, 72: 637-679, 1997.
17. Angeles, T. S., Steffler, C., Bartlett, B. A., Hudkins, R. L., Stephens, R. M., Kaplan, D. R., and Dionne, C. A. Enzyme-linked immunosorbent assay for trkA tyrosine kinase activity. Ann. Biochem., 236: 49-55, 1996.
18. Dionne, C. A., Camoratto, A. M., Jani, J. P., Emerson, E., Neff, N., Vaught, J. L., Murakata, C., Djakiew, D., Lamb, J., Bova, S., George, D., and Isaacs, J. T. Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751(KT6587). Clin. Cancer Res., 4: 1887-1898, 1998.
19. Mohammad, R. M., Dugan, M. C., Mohamed, A. N., Almatchy, V. P., Flake, T. M., Dergham, S. T., Shields, A. F., Al-Katib, A. A., Vainutis, V. K., and Sarkar, F. H. Establishment of a human pancreatic tumor xenograft model: potential application of preclinical evaluation for novel therapeutic agents. Pancreas, 16: 19-25, 1998.
20. Baba, M., Klein-Szanto, A. J., Trono, D., Obara, T., Yoakum, G. H., Masui, T., and Harris, C. C. Preneoplastic and neoplastic growth of xenotransplanted lung-derived human cell lines using deepithelialized rat tracheas. Cancer Res., 47: 573-578, 1987.
21. Momiki, S., Baba, M., Caamano, J., Iizasa, T., Nakajima, M., Yamaguchi, Y., and Klein-Szanto A. In vivo and in vitro invasiveness of human lung carcinoma cell lines. Invasion Metastasis, 11: 66-75, 1991.
22. Corbett, T. H., Valeriote, F. A., and Polin, L. Discovery of solid tumor activity agents using a soft-agar-colony-formation-disk-diffusion-assay. In: Cytotoxic Anti-Cancer Drugs: Models and Concepts for Drug Discovery and Development, pp. 35-89. Boston: Kluwer Academic, 1992.
23. Steele, G. D., Jr., Osteen, R. T., Winchester, D. P., Murphy, G. P., and Menck, H. R. Clinical highlights from the National Cancer Data Base: 1994. CA Cancer J. Clin., 44: 71-80, 1994.
24. George, D. J., Dionne, C. A., Jani, J., Angeles, T., Murakata, C., Lamb, J., and Isaacs, J. T. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res., 59: 2395-2401, 1999.
25. Gillespie, J., Dye, J. F., Schachter, M., and Guillou, P. J. Inhibition of pancreatic cancer cell growth in vitro by the tyrphostin group of tyrosine kinase inhibitors. Br. J. Cancer, 68: 1122-1126, 1993.
26. Schultz, R. M., Merriman, R. L., Toth, J. E., Zimmerman, J. E., Hertel, L. W., Andis, S. L., Dudley, D. E., Rutherford, P. G., Tanzer, L. R., and Grindey, G. B. Evaluation of new anti-cancer agents against the MIA PaCa-2 and Panc-1 human pancreatic carcinoma xenografts. Oncol. Res., 5: 223-228, 1993.
27. Smith, J. P., Stock, E., Orenberg, E. K., Yu, N. Y., Kanekal, S., and Brown, D. M. Intratumoral chemotherapy with a sustained-release drug delivery system inhibits growth of human pancreatic cancer xenografts. Anticancer Drugs, 6: 717-726, 1995.
28. Korc, M., Chandrasekar, B., Yamanaka, Y., Friess, H., Buchler, M., and Berger, H. G. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor α. J. Clin. Invest., 90: 1352-1360, 1992.
29. Kobrin, M. S., Yamanaka, Y., Friess, H., Lopez, M. E., and Korc, M. Aberrant expression of type 1 fibroblast growth factor receptor in human pancreatic adenocarcinomas. Cancer Res., 53: 4741-4744, 1993.
30. Itakurea, J., Ishiwata, T., Friess, H., Fujii H., Matsumoto, Y., Buchler, M. W., and Korc, M. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin. Cancer Res., 3: 1309-1316, 1997.
31. Ellis, L. M., Takahashi, Y., Fenoglio, C. J., Cleary, K. R., Bucana, C. D., and Evans, D. B. Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma. Eur. J. Cancer, 34: 337-340, 1998.
32. Redston, M. S., Caldas, C., Seymour, A. B., Hruban, R. H., daCosta, L., Yeo, C. J., and Kern, S. E. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res., 54: 3025-3033, 1994.
33. Kalthoff, H., Schmiegel, W., Roeder, C., Kasche, D., Schmidt, A., Luuer, G., Heinz-Gunter, T., Honold, G., Pantel, K., Riethmuller, G., Scherer, E., Mauer, J., Maacke, H., and Deppert, W. p53 and K-RAS alterations in pancreatic epithelial cell lesions. Oncogene, 8: 289-298, 1993.